---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-029240"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2023-08-17T23:59:59+00:00"
generated_at: "2026-06-11T07:41:43.540806+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# RenovoRx Q2 net loss $2.3M; positive Phase III data shows 8-month progression delay

## Summary
- Net loss $2.3M vs $2.6M year ago; cash $6.0M; R&D $1.9M, G&A $1.4M.
- Phase III TIGeR-PaC: 8-month progression delay, 6-month OS benefit, 65% fewer adverse events.
- Collaboration with Imugene to deliver oncolytic immunotherapy via TAMP platform for metastatic disease.
- Appointed Robert Spiegel to Board, Margaret Tempero to SAB, Leesa Gentry as SVP Clinical Ops.
- Closed $5M registered direct offering and concurrent private placement.

## SEC filing metadata
- accession: 0001493152-23-029240
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2023-08-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315223029240/0001493152-23-029240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315223029240/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-029240
- JSON: https://secwatch.observer/filing/0001493152-23-029240.json
- Plain text: https://secwatch.observer/filing/0001493152-23-029240.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.